Syntaxin is a newly formed biopharmaceutical research company focusing on discovery and development of new medicines derived from bacterial toxins to treat chronic diseases.

The biotechnology company was created in 2005 to develop complex proteins that can be used as biopharmaceuticals to treat neurological, respiratory and endocrine diseases.

The Company's biopharma product pipeline is based on exploiting the potent pharmacological properties of some microbial proteins, notably exotoxins.

 

Potential New Target

Potential

New Targets

Syntaxin novel drugs target many areas for therapeutic benefit.
Inflammation

Inflammation

Programme

Syntaxin are developing new treatments to tackle inflammatory diseases.